NeoVax
Phase 1Biologic
NeoVax is one of 90 biologic programs targeting Melanoma. It is currently in Phase 1.
3
Indications
5
Total Trials
4
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
177 competitors in Melanoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Lenvima
EisaiPhase 3
Opdualag
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Talimogene Laherparepvec
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioblastoma1 trial
Neoantigen1 trial
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Recruiting·—·Phase 1·NCT03219450·15 enrolled
Renal Cell Carcinoma1 trial
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
Active, not recruiting·—·Phase 1·NCT02950766·19 enrolled
Melanoma1 trial
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Active, not recruiting·—·Phase 1·NCT04930783·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NeoVax. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details